The focus of this presentation is on the most significant developments facing health care providers, payers and patients. Particular attention is devoted to the causes and consequences of the rapid growth in accountable care organizations (ACOs), medical homes, and multi-specialty health systems. The increasing importance of high quality nursing for health systems to be able to achieve critical quality metrics and cost containment is addressed. The talk concludes with an analysis of how Baby-Boomers, “Obamacare” and Medicare’s changing reimbursement models are accelerating the dramatic reshaping of health care organization, finance and delivery for all Americans (not just senior citizens).
Contact hours available until 11/3/2016.
Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.
Faculty, Planners and Authors Conflict of Interest Disclosure:
Planning Committee Disclosures:
Gina M. Powley, MSN, ANP-BC
Consultant: Ferring Pharmaceuticals, Astellas/Medivation
Leanne Schimke, MSN, CRNP-C, CUNP
Speaker's Bureau: Bayer-Xofigo, Amgen-Denosumab
There are no other disclosures to declare.
Commercial Support and Sponsorship:
No commercial support or sponsorship declared.
Accreditation Statement:
Society of Urologic Nurses and Associates is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
SUNA is a provider approved by the California Board of Registered Nursing, provider number, CEP 5556.
Objectives:
• Summarize the extent and significance of the major changes occurring in the health care industry.
• Describe the current status of the ACA.
• Discuss consolidation among Health Care Providers.
Information is provided on how to deliver a preoperative education class for men undergoing robotic radical prostatectomy. The goal of preoperative education is to adequately prepare patients and their families for surgery and improve postoperative outcomes.
Contact hours available until 11/3/2016.
Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.
Faculty, Planners and Authors Conflict of Interest Disclosure:
Planning Committee Disclosures:
Gina M. Powley, MSN, ANP-BC
Consultant: Ferring Pharmaceuticals, Astellas/Medivation
Leanne Schimke, MSN, CRNP-C, CUNP
Speaker's Bureau: Bayer-Xofigo, Amgen-Denosumab
There are no other disclosures to declare.
Commercial Support and Sponsorship:
No commercial support or sponsorship declared.
Accreditation Statement:
Society of Urologic Nurses and Associates is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
SUNA is a provider approved by the California Board of Registered Nursing, provider number, CEP 5556.
Objectives:
• Prepare a preoperative patient for urologic surgery by outlining expected post surgical outcomes.
• Outline the components of a successful pre-operative class.
The cause of pelvic floor disorders is often multifactorial, requiring a multidisciplinary approach. This lecture touches on one aspect of dysfunction, estrogen deprivation. Discussion is targeted at informing the participant on the role of estrogen loss and estrogen therapy options available to minimize the consequences of pelvic floor disorders.
Contact hours available until 11/3/2016.
Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.
Faculty, Planners and Authors Conflict of Interest Disclosure:
Planning Committee Disclosures:
Gina M. Powley, MSN, ANP-BC
Consultant: Ferring Pharmaceuticals, Astellas/Medivation
Leanne Schimke, MSN, CRNP-C, CUNP
Speaker's Bureau: Bayer-Xofigo, Amgen-Denosumab
There are no other disclosures to declare.
Commercial Support and Sponsorship:
No commercial support or sponsorship declared.
Accreditation Statement:
Society of Urologic Nurses and Associates is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
SUNA is a provider approved by the California Board of Registered Nursing, provider number, CEP 5556.
Objectives:
• Describe the clinical exam findings of the patient with PFD that may benefit from estrogen therapy.
• Describe the symptoms and specific PFDs that occur in the peri and post-menopausal woman.
• List the prescription and non-prescription hormonal options for the treatment of PFDs.
The evaluation and management of hypogonadism is discussed during this presentation. Topical, injectable, and implantable testosterone therapy are reviewed. Controversial issues associated with testosterone replacement therapy are also discussed.
Contact hours available until 11/3/2016.
Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.
Faculty, Planners and Authors Conflict of Interest Disclosure:
Planning Committee Disclosures:
Gina M. Powley, MSN, ANP-BC
Consultant: Ferring Pharmaceuticals, Astellas/Medivation
Leanne Schimke, MSN, CRNP-C, CUNP
Speaker's Bureau: Bayer-Xofigo, Amgen-Denosumab
There are no other disclosures to declare.
Commercial Support and Sponsorship:
No commercial support or sponsorship declared.
Accreditation Statement:
Society of Urologic Nurses and Associates is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
SUNA is a provider approved by the California Board of Registered Nursing, provider number, CEP 5556.
Objectives:
• List four components of the patient history when the patient presents with low testosterone.
• Name three rooutes of adminstration of testosterone replacement therapy.
• Describe the controverial issues surrounding testosterone replacement therapy.
Current treatment methods for urologic dysfunction or pelvic pain are often focused on only one aspect of care, for example, the bladder epithelium or vaginal tissue. While these methods can provide some relief, it is when they are performed in conjunction with an array of other treatment modalities that we have found both increased patient satisfaction and symptom improvement. This presentation includes a discussion about many different therapies including medications, trigger point injections, and topical treatments.
Contact hours available until 11/3/2016.
Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.
Faculty, Planners and Authors Conflict of Interest Disclosure:
Planning Committee Disclosures:
Gina M. Powley, MSN, ANP-BC
Consultant: Ferring Pharmaceuticals, Astellas/Medivation
Leanne Schimke, MSN, CRNP-C, CUNP
Speaker's Bureau: Bayer-Xofigo, Amgen-Denosumab
There are no other disclosures to declare.
Commercial Support and Sponsorship:
No commercial support or sponsorship declared.
Accreditation Statement:
Society of Urologic Nurses and Associates is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
SUNA is a provider approved by the California Board of Registered Nursing, provider number, CEP 5556.
Objectives:
• Identify two advantages to a multimodal approach to urologic dysfunction and pelvic pain.
Contact hours available until 11/3/2016.
Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.
Faculty, Planners and Authors Conflict of Interest Disclosure:
Planning Committee Disclosures:
Gina M. Powley, MSN, ANP-BC
Consultant: Ferring Pharmaceuticals, Astellas/Medivation
Leanne Schimke, MSN, CRNP-C, CUNP
Speaker's Bureau: Bayer-Xofigo, Amgen-Denosumab
There are no other disclosures to declare.
Commercial Support and Sponsorship:
Sponsored by Astellas Pharma US, Inc.
Accreditation Statement:
Society of Urologic Nurses and Associates is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
SUNA is a provider approved by the California Board of Registered Nursing, provider number, CEP 5556.
Objectives:
• Critically assess evidence based treatment options for castration-resistant prostate cancer focusing on new and emerging therapies.
• Recognize and manage disease and treatment related complications with the goal of developing a plan of care to improve quality of life and continuation of care.
• Summarize the available efficacy and safety data related to new and novel agents used for the treatment of prostate cancer that has progressed during androgen-blockade.
• Evaluate patient and disease characteristics and identify opportunities to provide.
• comprehensive care and counsel of patients with metastatic CRPC.
In 2000, the first robotic prostatectomy was performed. Since then, great strides in robotic urologic surgery have been attained. This presentation discusses robotic partial and total nephrectomy, and robotic adrenalectomy surgery.
Contact hours available until 11/3/2016.
Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.
Faculty, Planners and Authors Conflict of Interest Disclosure:
Planning Committee Disclosures:
Gina M. Powley, MSN, ANP-BC
Consultant: Ferring Pharmaceuticals, Astellas/Medivation
Leanne Schimke, MSN, CRNP-C, CUNP
Speaker's Bureau: Bayer-Xofigo, Amgen-Denosumab
There are no other disclosures to declare.
Commercial Support and Sponsorship:
No commercial support or sponsorship declared.
Accreditation Statement:
Society of Urologic Nurses and Associates is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
SUNA is a provider approved by the California Board of Registered Nursing, provider number, CEP 5556.
Objectives:
• Identify recent strides in robotic urologic surgery.
• Describe Robot-assisted Nephrectomy & Partial Nephrectomy.
• Describe Rotot-assisted Adrenalectomy.